Researchers at LMU Munich have developed the first human cell model to accurately mimic the adult brain's tau protein mutations linked to Alzheimer's and other dementias. The model overcomes ...

The gene editing treatment targets the relatively common 1717-1G>A splicing mutation, which does not respond to many current CF therapies.

Researchers at LMU have developed a human cell model that replicates key mechanisms of neurodegenerative diseases—with ...

Most asset managers try to track the market. Through ARK Investment, Cathie Wood is trying to get ahead of the market’s best ...

In the most recent trading session, CRISPR Therapeutics AG (CRSP) closed at $56.42, indicating a +1.58% shift from the previous trading day.

Whenever people come across anything that genuinely fascinates them, one of their first instincts is to share it with someone ...

CRISPR Therapeutics stock snapshot and recent performance CRISPR Therapeutics (CRSP) has drawn investor attention after its recent trading, with the stock last closing at US$57.69 and posting a 0.5% ...

To accelerate discovery, scientists from ATCC and the Broad Institute collaborated to engineer a panel of drug-resistant NSCLC models using CRISPR gene editing and gene overexpression techniques.

CRISPR-based modification of haematopoietic stem cells has enabled durable, boostable antibody production in mouse models ...

The human immunodeficiency virus (HIV), which is the cause of AIDS, is a master of deception, using just nine genes to hijack ...